- KR₩19tn
- KR₩19tn
- KR₩216bn
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
Refile: Merck plans to launch US subcutaneous version of Keytruda on October 1
Merck says Keytruda injection on par with approved IV version in trial
Brief: Alteogen Receives Ministry Of Food And Drug Safety Approval For Tergase®
Brief: Alteogen says its Drug Tergase Shows Excellent Immunogenicity Profile
Brief: Altos Biologics Completes Patient Enrollment In Global Phase 3 Clinical Trial Of Eylea
Brief: Alteogen Announces Completion Of Phase 1 Clinical Trial Of Aflibercept Biosimilar In Wet AMD Patients
Brief: Alteogen Enters Into Global License Agreement With A Top Pharmaceutical Company For Use Of Its Hybrozyme Technology
Brief: Alteogen's Gastric Cancer Drug Gets FDA Approval For Orphan Drug Designation
Brief: Alteogen receives China patent
Brief: Alteogen to buy land for 2.61 bln won for research installation use
Brief: Alteogen receives U.S. patent
Brief: Alteogen raises 32 bln won in private placement
Brief: Alteogen to raise 32 bln won in private placement
Brief: Alteogen receives patent
Brief: Alteogen receives U.S. patent